| Lodestar Minerals Limited (LSR) ORDINARY FULLY PAID |
Materials |
$15 |
Visible Copper and IOCG Mineralisation Confirmed in Chile
|
29 Apr 2026 10:34AM |
$0.028 |
$0.010 |
fallen by
64.29%
|
|
LSR - Price-sensitive ASX Announcement
Full Release
Key Points
- Visible copper observed in second drill hole L3SDD004.
- Drilling at Three Saints IOCG Project in Chile.
- IOCG-style mineralised system confirmed.
- 700m strike length of mineralisation indicated.
- Hydrothermal alteration and sulphides present.
- Results from drill holes expected end of May and early July.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clime Capital Limited (CAM) ORDINARY FULLY PAID |
Financials |
$96 |
Notification of cessation of securities - CAM
|
29 Apr 2026 10:33AM |
$0.700 |
$0.680 |
fallen by
2.86%
|
|
| Winchester Energy Limited (WEL) ORDINARY FULLY PAID |
Energy |
$2 |
Letter to Shareholders
|
29 Apr 2026 10:30AM |
$0.002 |
$0.001 |
fallen by
50%
|
|
| Perseus Mining Limited (PRU) ORDINARY FULLY PAID |
Materials |
$6,855 |
Update - Notification of buy-back - PRU
|
29 Apr 2026 10:29AM |
$5.520 |
$5.150 |
fallen by
6.70%
|
|
| Hydrocarbon Dynamics Limited (HCD) ORDINARY FULLY PAID |
Energy |
$0 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Apr 2026 10:28AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
| Winchester Energy Limited (WEL) ORDINARY FULLY PAID |
Energy |
$2 |
Notice of AGM
|
29 Apr 2026 10:27AM |
$0.002 |
$0.001 |
fallen by
50%
|
|
| Revolver Resources Holdings Ltd (RRR) ORDINARY FULLY PAID |
Materials |
$23 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Apr 2026 10:22AM |
$0.071 |
$0.075 |
risen by
5.63%
|
|
RRR - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly activities report for the period ended 31 March 2026.
- Focus on the Dianne Copper Mine Project with pre-construction activities completed.
- Successful capital raising of approximately A$2.6 million.
- Cash outflows included exploration and evaluation expenditure and administrative costs.
- Revolver had approximately A$1.219 million in cash at the end of March 2026.
- Targeting a final investment decision on the Dianne project with copper output expected within 12 months following the decision.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Syntara Limited (SNT) ORDINARY FULLY PAID |
Health Care |
$37 |
Proposed issue of securities - SNT
|
29 Apr 2026 10:21AM |
$0.032 |
$0.019 |
fallen by
40.63%
|
|
| Syntara Limited (SNT) ORDINARY FULLY PAID |
Health Care |
$37 |
Proposed issue of securities - SNT
|
29 Apr 2026 10:21AM |
$0.032 |
$0.019 |
fallen by
40.63%
|
|
| Syntara Limited (SNT) ORDINARY FULLY PAID |
Health Care |
$37 |
Equity Raising Presentation
|
29 Apr 2026 10:21AM |
$0.032 |
$0.019 |
fallen by
40.63%
|
|
SNT - Price-sensitive ASX Announcement
Full Release
Key Points
- Syntara Limited is conducting a two tranche non-underwritten placement to raise approximately A$8 million.
- The placement includes issuing approximately 296.3 million new fully paid ordinary shares.
- The offer price is set at A$0.027 per new share, representing a discount to recent trading prices and VWAPs.
- Funds raised will be used for trial readouts, MF licensing discussions, and Phase 2b MF study preparations.
- Canaccord Genuity and Euroz Hartleys are acting as Joint Lead Managers and Joint Bookrunners.
- The company’s pipeline includes assets such as Amsulostat, SNT-4728, and SNT-9465.
- Syntara aims to leverage its assets to negotiate licensing deals within the financial runway provided by the raise.
- The company has FDA IND and orphan drug designation for Amsulostat in myelofibrosis.
- Preparations are underway for a Phase 2b study expected to commence in Q4 2026.
- Syntara's business is backed by specialist healthcare investors and has a strong track record in asset partnerships.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Syntara Limited (SNT) ORDINARY FULLY PAID |
Health Care |
$37 |
$8m placement and share purchase plan
|
29 Apr 2026 10:21AM |
$0.032 |
$0.019 |
fallen by
40.63%
|
|
SNT - Price-sensitive ASX Announcement
Full Release
Key Points
- Syntara Limited announced a capital raising of A$8 million via institutional placement.
- An additional A$2 million is aimed to be raised through a share purchase plan (SPP).
- The funds will support clinical trial programs and preparatory work for a Phase 2b study.
- Placement was divided into two tranches, with settlement dates in May and June 2026.
- The placement price was set at A$0.027 per share, at a discount to recent trading prices.
- Strong support was received from existing and new institutional investors.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atomos Limited (AMS) ORDINARY FULLY PAID |
Consumer Discretionary |
$15 |
NAB 2026 Product and Ecosystem Update
|
29 Apr 2026 10:18AM |
$0.021 |
$0.010 |
fallen by
52.38%
|
|
| Starpharma Holdings Limited (SPL) ORDINARY FULLY PAID |
Health Care |
$293 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Apr 2026 10:15AM |
$0.705 |
$0.695 |
fallen by
1.42%
|
|
SPL - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA alignment confirmed for DEP® HER2 first-in-human phase 1 clinical study.
- Strategic partnerships and platform validation advanced through engagements at JP Morgan and BIO-Europe.
- Publication of research collaboration with Genentech in the Journal of Pharmaceutical Sciences.
- Preparation for first-in-human phase 1 study of DEP® HER2 radiotherapeutic candidate.
- Starpharma's cash balance was $14.1 million as of 31 March 2026.
- Net operating cash outflows for the quarter were $3.9 million.
- Continued commercial activities for Viraleze™ with an increase in web sales.
- Presented at the Ignite Investment Summit in Hong Kong.
- Estimated quarters of funding available is 3.7 quarters.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sparc Technologies Limited (SPN) ORDINARY FULLY PAID |
Materials |
$34 |
Trading Halt
|
29 Apr 2026 10:14AM |
$0.345 |
$0.285 |
fallen by
17.39%
|
|
SPN - Price-sensitive ASX Announcement
Full Release
Key Points
- Sparc Technologies Limited (ASX: SPN) requested a trading halt.
- The trading halt will remain in place until either the commencement of normal trading on Friday, 1 May 2026, or until the release of an announcement.
- The trading halt is requested to manage continuous disclosure obligations.
- The purpose of the halt is related to a material update concerning ecosparc®.
- The company expects to make the announcement before the commencement of normal trading on the mentioned date.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rivco Australia Ltd (RIV) ORDINARY FULLY PAID |
Utilities |
$227 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Apr 2026 10:11AM |
$1.450 |
$1.425 |
fallen by
1.72%
|
|
RIV - Price-sensitive ASX Announcement
Full Release
Key Points
- Operating receipts totaled $4.4 million for the quarter.
- Staff costs were $0.21 million, and administration and corporate costs were $0.49 million.
- Investing cash outflows of $2.2 million for acquiring water entitlements.
- Financing cash outflows included a $2.0 million debt repayment.
- Net cash from operating activities was $3.223 million.
- Net decrease in cash and cash equivalents for the period was $2.531 million.
- Cash and cash equivalents at the end of the period were $1.5 million.
- The company had $20.5 million of debt drawn under its $40.0 million facility.
- A fully franked dividend of 3.72 cents per share was declared.
- Strategic priorities include increasing earnings stability and portfolio optimization.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Otto Energy Limited (OEL) ORDINARY FULLY PAID |
Energy |
$24 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
29 Apr 2026 10:05AM |
$0.005 |
$0.005 |
fallen by
0%
|
|
OEL - Price-sensitive ASX Announcement
Full Release
Key Points
- Green #1 well performed as expected, while Green #2 experienced an increased water-to-gas ratio.
- Production from Green #1 and #2 was 58.8 Mboe, a 10% decrease from the previous quarter.
- Revenue increased by 10% due to higher natural gas and oil prices.
- Production and sales revenue details for SM 71 and Lightning projects are provided.
- Financial outcomes impacted by price changes in commodities market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$13 |
Change in substantial holding
|
29 Apr 2026 10:04AM |
$0.125 |
$0.058 |
fallen by
53.60%
|
|
| Humm Group Limited (HUM) ORDINARY FULLY PAID |
Financials |
$232 |
Further update regarding EGM
|
29 Apr 2026 10:03AM |
$0.635 |
$0.460 |
fallen by
27.56%
|
|
| VanEck Morningstar Australian Moat Income ETF (DVDY) |
Financials |
$31 |
Change of reference index, ETF name and ASX code
|
29 Apr 2026 10:03AM |
$20.000 |
$19.900 |
fallen by
0.50%
|
|
| Clever Culture Systems Limited (CC5) ORDINARY FULLY PAID |
Health Care |
$39 |
Investor Conference Call Notification
|
29 Apr 2026 10:01AM |
$0.024 |
$0.018 |
fallen by
25%
|
|
| Noviqtech Limited (NVQ) ORDINARY FULLY PAID |
Information Technology |
$16 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Apr 2026 10:01AM |
$0.029 |
$0.039 |
risen by
34.48%
|
|
NVQ - Price-sensitive ASX Announcement
Full Release
Key Points
- NoviqTech Limited ended the March 2026 quarter with cash reserves of $1.1 million.
- The company completed a capital raising of $1.5 million to fund the acquisition of Coralia Pty Ltd and accelerate its commercial plans.
- A strategic acquisition was made with Coralia Pty Ltd, a Biochar Carbon Dioxide Removal company targeting AI and data centre sectors.
- NoviqTech entered a Memorandum of Understanding (MOU) with A Healthier Earth for a long-term carbon credit offtake from the Great Barrier Reef Biochar Project.
- Operating expenses for the quarter included $273,000 in staff costs and $144,000 in administration and corporate costs.
- Net cash used in operating activities was $322,000 for the quarter.
- Coralia signed a Research Partnership Agreement with Swinburne University of Technology to explore biochar applications in low-carbon concrete.
- A strategic asset review is underway to reduce cash burn and align resources with core business goals.
- The outstanding debt owed to PEAK Asset Management Pty Ltd and Copeak Pty Ltd was converted to equity.
- Termination of the Master Services Agreement with MorphoTech is expected to cut costs by approximately $62,500 per month.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biotron Limited (BIT) ORDINARY FULLY PAID |
Health Care |
$8 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 Apr 2026 10:01AM |
$0.003 |
$0.003 |
fallen by
0%
|
|
BIT - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed integration of Sedarex Limited into Biotron.
- Progressed submission for European Medicines Agency for SedRx.
- Demonstrated BIT-HBV001's activity against Hepatitis Delta Virus.
- Raised $878,733 from rights issue shortfall.
- Appointed Dr Graeme Wald as Non-Executive Director.
- Reported expenditures of $128,000 on R&D and $142,000 on staff costs.
- Net cash used in operating activities was $686,000.
- Cash and cash equivalents at end of quarter were $1.776 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Delta Lithium Limited (DLI) ORDINARY FULLY PAID |
Materials |
$115 |
Final Director's Interest Notice
|
29 Apr 2026 10:00AM |
$0.240 |
$0.160 |
fallen by
33.33%
|
|
| Sparc Technologies Limited (SPN) ORDINARY FULLY PAID |
Materials |
$34 |
Pause in Trading
|
29 Apr 2026 9:59AM |
$0.330 |
$0.285 |
fallen by
13.64%
|
|
SPN - Price-sensitive ASX Announcement
Full Release
Key Points
- Sparc Technologies Limited is identified by the security code SPN.
- A temporary trading pause has been announced.
- The pause in trading is pending further announcements.
- The announcement was made by Riley Jackson from ASX Listings Compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Betmakers Technology Group Ltd (BET) ORDINARY FULLY PAID |
Consumer Discretionary |
$179 |
Quarterly Presentation
|
29 Apr 2026 9:59AM |
$0.170 |
$0.160 |
fallen by
5.88%
|
|
BET - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 12.6% compared to the prior corresponding period.
- Adjusted EBITDA of $3.4 million, improved by $2.2 million from Q3 FY25.
- Gross margin expanded to 67.0%, up from 63.9% in Q3 FY25.
- Strong operating cash flow maintained at $2.8 million.
- Successful go-live of CrownBet and completion of LVDC acquisition.
- Technology-led operating model supports ongoing cost base optimization.
- AI-powered innovation and scalable platform support future growth.
- Additional new customers anticipated in Q4 FY26.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
